Start-Up Nation Poised To Corner the Global Medical Marijuana Market
Medical marijuana is on track to become a booming industry in Israel, with 36 Israeli companies now doing clinical research on cannabis, according to a report in the Economist.
That figure comes from Saul Kaye, the CEO of the venture fund and technology incubator iCAN.
Israel’s health ministry is licensing a list of about 100 doctors to prescribe the drug, and regular pharmacists will be able to stock it.
What’s more, in August, the agriculture minister announced that local growers will soon be allowed to export their crop.
There’s a reason why medical marijuana research is blossoming in Israel, even though the country’s right wing government is against legalization of marijuana for recreational use.
Israel’s strong agricultural and medical sectors, combined with its reputation as “startup nation” have primed it for developing marijuana for medical use.
What’s more, wrote the Economist, it has a 60-year head start on the United States where marijuana research is just beginning.
While the United States is just beginning to review laws that hamper research with an eye to possibly changing them, Israeli scientists have been looking into the topic for decades. Raphael Mechoulam, considered the father of cannabis research, is an Israeli professor at the Hebrew University of Jerusalem.
Israel researchers are looking into uses of medical marijuana for a range of conditions beyond pain relief, such as Alzheimer’s disease and Tourette’s syndrome.
Contact Naomi Zeveloff at [email protected] or on Twitter @naomizeveloff
A message from our CEO & publisher Rachel Fishman Feddersen
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.
At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse.
Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.
— Rachel Fishman Feddersen, Publisher and CEO